Every Form 4 that Gentex Corp (GNTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow GNTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GNTX filings page.
KENNEDY JOHN C reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director John C. Kennedy reported an equity award of 5,626 shares of Common Stock. The shares were granted at no cash cost to him as a compensation award and will vest 100% one year from the grant date. Following this grant, he holds 5,626 shares directly.
Zang Ling reported acquisition or exercise transactions in this Form 4 filing.
Gentex Corp director Ling Zang reported an equity award of 5,626 shares of Common Stock. The shares were granted at no cost as a compensation award and will vest 100% one year from the grant date. Following this grant, Zang directly holds 35,599 Gentex shares.
WALKER BRIAN C reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Brian C. Walker received a stock award of 5,626 shares of common stock as equity compensation. The shares were granted at no cash cost and will vest 100% one year from the grant award date. Following this award, Walker directly holds 29,831 common shares.
Starkoff Kathleen reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Kathleen Starkoff reported receiving a stock award of 5,626 shares of Common Stock as a compensation-related grant. The shares were awarded at no cash cost and increase her direct holdings to 36,770 shares following the transaction. According to the disclosure, the entire award vests 100% one year from the grant award date, meaning she will gain full ownership after the one-year vesting period.
GENTEX CORP director Richard O. Schaum reported an equity award of 5,626 shares of Common Stock, received at a price of $0.00 per share as a grant or award acquisition. These shares vest 100% one year from the grant award date. Following this transaction, Schaum directly holds 87,069 shares.
Pink Billy reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Billy Pink reported receiving an equity award of 5,626 shares of Common Stock. The award was granted at a stated price of $0.00 per share as a compensation grant. According to the footnote, these shares vest 100% one year from the grant award date. Following this award, Pink directly holds 15,329 shares of Gentex common stock.
DEUR GARTH reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Garth Deur received a grant of 5,626 shares of Common Stock as a compensation award. The award was reported at a price of $0.00 per share, indicating it is not an open-market purchase but a share grant. Following this transaction, his directly held position increased to 20,045 shares of Common Stock. A footnote explains that these granted shares vest 100% one year from the grant award date, meaning he will gain full ownership rights to the entire award after that one-year vesting period.
BROWN LESLIE L reported acquisition or exercise transactions in this Form 4 filing.
GENTEX CORP director Leslie L. Brown received a grant of 5,626 shares of Common Stock, which vest 100% one year from the grant date. After this award, Brown directly holds 41,988 shares. This is a compensation-related equity grant rather than an open-market purchase.
Gentex Corp director Brian C. Walker reported an open-market sale of 5,939 shares of Gentex common stock at an average price of $22.9752 per share. After this transaction, he directly owns 24,205 Gentex shares, indicating he retains a meaningful continuing stake in the company.
GENTEX CORP director Joseph B. Anderson Jr. reported an open-market sale of 5,939 shares of Common Stock on May 15, 2026 at an average price of $22.9752 per share. Following this transaction, his directly held Common Stock position reported in this filing is 0 shares.
Gentex Corp director Leslie L. Brown reported a combination of option exercises and share sales. On May 5, 2026, Brown sold 10,782 shares of Gentex common stock in an open-market sale at a weighted average price of $22.847 per share.
On the same date, Brown exercised stock options to acquire a total of 14,000 shares of common stock, including 7,000 options at $18.70 and 7,000 options at $15.74 per share. Following these transactions, Brown directly owned 36,362 common shares. The exercised options came from non‑employee director grants originally exercisable in 2016 and 2017 with expirations in 2026 and 2027.
Gentex Corp director Richard O. Schaum exercised stock options and sold shares in a routine portfolio move. He exercised options covering 7,000 shares of Common Stock at $15.74 per share and sold 4,815 Common shares in an open‑market sale at a weighted average price of $23.312.
Following these transactions, Schaum directly owns 81,443 Gentex Common shares. No remaining derivative option position is reported in this filing.
GENTEX CORP Chief Technology Officer Neil Boehm reported multiple stock transactions involving company common stock. He received a grant of 14,953 shares on February 19, 2026 and a grant of 31,993 performance-based shares on February 17, 2026, both at a stated price of $0.00 per share, reflecting equity awards rather than purchases.
Also on February 17, 2026, shares were withheld to cover tax obligations at $24.89 per share in two transactions totaling 17,768 shares, and he executed open-market sales at $24.82 per share in two transactions totaling 11,248 shares. After these transactions, he directly owned 58,951 shares of Gentex common stock.
GENTEX CORP General Counsel Ryan Scott P reported multiple stock transactions in Gentex common shares. He acquired 11,000 shares on February 19, 2026 and 25,782 shares on February 17, 2026 as grants, both at a stated price of $0.00 per share. The 25,782-share grant is performance-based, with the total tied to long-term incentives and vesting 100% three years from the grant date.
On February 17, 2026, he disposed of shares to cover tax obligations, delivering 11,492 shares and 2,907 shares at $24.89 per share. He also executed open-market sales of 7,145 shares and 1,879 shares at an average price of $24.7302 per share, totaling 9,024 shares sold. After these transactions, he directly owned 44,279 Gentex shares.
Gentex Corp Chief Financial Officer Kevin C. Nash reported multiple stock transactions involving common shares. He acquired 13,880 shares on February 19, 2026 as a grant at no cost, increasing his holdings in that transaction to 73,310 shares.
On February 17, 2026, he received an additional grant of 38,181 performance-based shares, with the total number tied to long-term performance incentives and vesting 100% three years from the grant award date. The Form 4 also shows tax-withholding dispositions totaling 16,864 and 4,306 shares at $24.8900 per share, and open-market sales of 6,317 and 5,568 shares at $24.9767 per share.
After these transactions, Nash directly owned 59,430 common shares of Gentex Corp.
Gentex Corporation President and CEO Steven R. Downing reported multiple stock transactions involving company common shares. He received two equity awards, acquiring 43,492 shares on February 19, 2026 and 124,311 performance-based shares on February 17, 2026, both at a stated price of $0.00 per share.
The 124,311 performance-based shares were granted under long-term performance incentives and vest 100% three years from the grant award date. On February 17, 2026, shares were also disposed of to cover tax obligations, with 54,314 and 14,018 shares withheld at $24.89 per share, and 35,000 shares sold in an open-market transaction at an average price of $24.7457 per share. Following these transactions, Downing directly owned 211,670 Gentex common shares.
Gentex Corporation vice president of sales Matthew Chiodo reported a mix of stock awards, tax-related share dispositions, and open-market sales of common stock. On February 17, he received a grant of 28,269 performance-based shares, with the number tied to long-term performance incentives and vesting 100% three years from the grant date. That same day, Form 4 data shows tax-withholding dispositions of shares at about $24.89 per share and open-market sales totaling 19,827 shares at about $25.03 per share. On February 19, he received an additional award of 12,047 shares of common stock, bringing his directly held stake to 47,148 shares after the reported transactions.